EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication






American Journal of Veterinary Research 50(10): 1672-1677

Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication

The antiviral activities of 9-(2-hydroxyethoxymethyl)guanine (acyclovir; ACV) either alone or combined with recombinant human leukocyte (alpha) A/D interferon (rHuIFN-alpha) against feline herpesvirus type 1 (FHV-1) were evaluated in feline embryo cell cultures, using an infectivity-inhibition assay. In ACV-treated cultures, the 50% inhibitory dose (ID50) was approximately 10 to 20 micrograms of ACV/ml. Maximal inhibition of FHV-1 infectivity (range, 3.4 to 4.2 log10 TCID50) was observed when high test doses of ACV (125 or 250 micrograms/ml) were given 1 to 6 hours after infection. Although mild inhibition (range, 0.3 to 1.6 log10 TCID50) of virus was observed at lower drug doses (10 to 62.5 micrograms/ml), FHV-1 was relatively resistant to ACV and required higher minimal inhibitory doses than those reported for other herpesviruses. However, when ACV was combined with 10 or 100 U of rHuIFN-alpha/ml, synergistic antiviral effects were associated with ACV dosage of 10 to 62.5 micrograms/ml. Antiviral activities resulting from use of the combined drugs permitted nearly eightfold reduction in the dose of ACV required to achieve maximal inhibition of FHV-1. Significant (P less than 0.01) synergistic interactions with ACV resulted when the rHuIFN-alpha was given before or after infection; at the lower doses of ACV, however, rHuIFN-alpha pretreatment was more effective. Although dosages of either greater than or equal to 62.5 micrograms of ACV/ml or 100 U of rHuIFN-alpha/ml were cytosuppressive in control cell cultures, additive anticellular effects were not observed at synergistic combinations of ACV and 10 U of rHuIFN-alpha/ml.


Accession: 001962315

PMID: 2552872



Related references

Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon on in vitro replication of feline herpesvirus-1. American Journal of Veterinary Research 67(8): 1406-1411, 2006

Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. American Journal of Veterinary Research 49(8): 1329-1335, 1988

Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrobial Agents & Chemotherapy 28(5): 698-699, 1985

Synergistic anticellular and antiviral activities of human recombinant interferon gamma and interferon beta. Journal of Pharmacobio-Dynamics 9(11): 871-878, 1986

Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta. Journal of Pharmacobio-Dynamics 9(11): 871-878, 1986

Studies on the in vitro biological activities of recombinant bovine tumor necrosis factor rbotnf alpha i. synergistic antiviral efficacy of rbotnf alpha recombinant bovine interferon gamma rbo ifn gamma and their combination. Antiviral Research 10(1-3): 71-82, 1988

Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus. Antimicrobial Agents and ChemoTherapy 24(3): 325-332, 1983

Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice. Antimicrobial Agents and ChemoTherapy 28(1): 1-4, 1985

Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. Journal of Infectious Diseases 158(2): 378-385, 1988

Antiviral effect of recombinant interferon-alpha on hepatitis A virus replication in human liver cells. Comptes Rendus de L'academie des Sciences. Serie Iii, Sciences de la Vie 317(1): 94-97, 1994